Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy

por Lennie, Janelle L., Mondick, John T., Gastonguay, Marc R.
Publicado 2022

Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy

por Feng, Yan, Gastonguay, Marc R, Pollock, Bruce G, Frank, Ellen, Kepple, Gail H, Bies, Robert R
Publicado 2011

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

por Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Publicado 2019

Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome

por Eudy‐Byrne, Rena, Zane, Nicole, Adeniyi‐Jones, Susan C., Gastonguay, Marc R., Ruiz‐Garcia, Ana, Kaushal, Gagan, Kraft, Walter K.
Publicado 2021

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

por Krishnaswami, Sriram, Austin, Daren, Della Pasqua, Oscar, Gastonguay, Marc R., Gobburu, Jogarao, van der Graaf, Piet H., Ouellet, Daniele, Tannenbaum, Stacey, Visser, Sandra A. G.
Publicado 2020

Polymorphisms in Cytochrome P450 are associated with Extensive Efavirenz Pharmacokinetics and CNS Toxicities in an HIV Cohort in Botswana

por Vujkovic, Marijana, Bellamy, Scarlett L., Zuppa, Athena F., Gastonguay, Marc R., Moorthy, Ganesh S, Ratshaa, Bakgaki, Han, Xiaoyan, Steenhoff, Andrew P., Mosepele, Mosepele, Strom, Brian L., Bisson, Gregory P., Aplenc, Richard, Gross, Robert
Publicado 2018